Reading NMTC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NMTC free→Reading NMTC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NMTC free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak. Earnings quality cannot be assessed since the company is unprofitable. Management's recent track record has been unsteady, with frequent changes. Risk is high, and the sector backdrop is a headwind. Peer multiples imply a price about 59% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk. This pattern occurs because it trades below peer multiples, but recent financials are weak. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $3.25. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $3.25 NMTC trades at 3× p/s, in line with its 3× p/s peer median. Our $4.90 fair value reflects that, medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 59% below a flat-multiple fair value, below our forecast of about 100%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 1.07x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates.
9 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.18 → $-0.22 (-20.4% / 30d). 1 raised, 0 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$250.
How much price usually moves either way.
On a bad day, this stock has moved -$781.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,906.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The earnings report will show how much money the company makes. This helps us see how well it can grow.
Confirms one read:The earnings report shows that revenue growth is speeding up again. This is better than last quarter.
Confirms the other:The earnings report shows that revenue is still going down or not changing. This is a concern.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for NMTC yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. On May 21, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of NeuroOne Medical Technologies Corporation (the “Company”), after discussion with management, determined that the Company’s previously issued interim financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed on May 12, 2026 (the “Previ…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Roughly priced in line with peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
NMTC NeuroOne Medical Technologies Corp | Typical Show detailsSector percentile: 40 of 100 | inexpensive | high |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 92 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 70 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The company aims to achieve at least $10.5 million in product revenue for fiscal year 2026.
The company aims to achieve product revenue of $2.4 million in the second quarter of fiscal 2026.
Why it matters: The health care sector is maturing. Changes in revenue growth can impact NMTC's performance and outlook.
Confirms one read:Health care sector revenue growth re-accelerates back toward its highs.
Confirms the other:Health care sector revenue growth continues to decelerate.
Why it matters: The debt issuance could impact the company's cash flow and future investments. Investors will want to see how it affects financial health.
Confirms one read:A press release detailing the terms and expected use of proceeds from the debt issuance.
Confirms the other:No further information released about the debt issuance or its terms.
Other Events. On December 21, 2022, NeuroOne Medical Technologies Corporation (the “Company”) entered into a Capital on Demand™ Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC (“JonesTrading”) pursuant to which the Company may sell from time to time shares of its common stock, par value $0.001 (the “Shares”) through any method permitted that is deemed an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, und…
and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 24, 2026, Ronald McClurg notified NeuroOne Medical Technologies Corporation (the “Company”) of his intention to retire as the Company’s Chief Financial Officer. The effective date of Mr. McClurg’s retirement as Chief Financial Officer will be June 30, 2026. Following his retirement as an officer, Mr. McClurg will remain employed by the Com…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 25, 2026, the Board of Directors (the “Board”) of NeuroOne Medical Technologies Corporation (the “Company”) adopted a First Amendment (the “Amendment”) to the NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan (the “2025 Equity Incentive Plan”). On April 3, 2026, at the Annual Meeting (as defined below), the stockholde…